HOME >> BIOLOGY >> NEWS
Joslin Diabetes Center announces new national Joslin Vision Network affiliation program

BOSTON -- Joslin Diabetes Center has launched a new affiliation program designed to bring Joslin's world-class vision resources to local communities across the United States and beyond. The first Joslin Vision Network (JVN) affiliation is with Koch Eye Associates in Warwick, R.I.

Diabetic retinopathy is one of the most significant complications of diabetes. The problem is compounded because the disease is asymptomatic, especially in the early stages when it is most treatable. Missed or inadequate care can lead to devastating results. But with early detection and appropriate treatment, vision loss can be prevented.

"Diabetes is the leading cause of vision loss and blindness in the United States, and yet most patients do not get recommended care," said Alan M. Jacobson, M.D., Senior Vice President, Joslin Strategic Initiatives Division. "By creating the JVN Affiliate Program and partnering with leading organizations such as Koch Eye Associates, we can bring Joslin's proven techniques in managing eye disease to the millions of Americans across the country at risk for losing their vision from diabetic retinopathy."

The JVN is the only diagnostic retinal evaluation service offering patients a pain-free and non-dilated diabetic eye evaluation that has been validated against dilated eye exams by retinal specialists. The JVN is already in use at more than 35 federal health care sites in 15 states, and implementation is planned at the Joslin Diabetes Center Affiliate in Bahrain.

"Our new Joslin affiliation allows us to offer world-class expertise to the estimated 100,000 people in Rhode Island with diabetes, and we are proud to be the first member of the JVN Affiliate Program," said Peter Koch, Chief Executive Officer, Koch Eye Associates. "The Koch physicians will care for our patients with diabetes-related eye disease, and we will collaborate with Joslin on research and care advancements."

The new Joslin Vision Network Affiliat
'"/>

Contact: Marjorie Dwyer
marjorie.dwyer@joslin.harvard.edu
617-732-2415
Joslin Diabetes Center
27-Jun-2005


Page: 1 2

Related biology news :

1. Joslin study indicates insulin receptors play a critical role in promoting islet growth
2. Joslin researchers discover a surprising culprit in the search for causes of diabetic birth defects
3. Joslin study reveals how a specific fat type can protect against weight gain and diabetes
4. Joslin discovers protein that causes blood vessel leakage and swelling with diabetic retinopathy
5. Joslin-led study uncovers role of appetite hormone MCH in insulin production
6. Joslin Diabetes Center study examines insulin pump therapy in adolescents
7. Joslin Diabetes Center in Boston establishes first affiliate in Canada
8. Walgreens and Joslin Diabetes Center form broad alliance to improve diabetes outcomes
9. Joslin awards Victory Medal to New York man living 75 years with type 1 diabetes
10. Joslins new book demystifies nutrition and meal planning for people with diabetes
11. Joslin study refutes recent report that bone marrow can replenish female oocytes

Post Your Comments:
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
(Date:4/16/2015)... 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced today the appointment of ... as Chief Operating Officer (COO). Cooper brings to ... developing clinical diagnostic and biotechnology platforms in the ... Cooper’s extensive career transcends the field of medical ...
(Date:4/16/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. ... the orphan disorder, neurotrophic keratopathy (NK), and a ... (DES) in the U.S.  Both trials will be ... Each of these eye disorders was being targeted ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Switzerland , April 16, 2015 /PRNewswire/ ... Debiopharm Group ™ , a Swiss-based global biopharmaceutical ... medical needs as well as companion diagnostics, ... investigational compounds Debio 1143 (SMAC mimetic) and Debio 1347/CH5183284 ... the 2015 Annual meeting of the American Association for Cancer Research ...
Breaking Biology Technology:OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
Cached News: